Revolution Medicines, Inc.
RVMDDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
5
Next Catalyst
This month
Market Overview
Stock performance and key metrics
7 upcoming, 1 past
Gemcitabine Phase 3 Results Expected
Primary completion for Gemcitabine trial (NCT06625320) in Pancreatic Cancer
doubled survival in Phase 3 pancreatic cancer study
Sourcegemcitabine Phase 2 Est. Readout
Primary completion for gemcitabine trial (NCT06445062) in Colorectal Cancer
SourceRMC-6236 Phase 3 Results Expected
Primary completion for RMC-6236 trial (NCT06625320) in Pancreatic Cancer
doubled survival in pancreatic cancer
Source4 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Gemcitabine
Pancreatic Cancer
daraxonrasib
NSCLC (Non-small Cell Lung Cancer)
RMC-6236
Colorectal Cancer
RMC-4630
Non-Small Cell Lung Cancer
RMC-6291
Non-Small Cell Lung Cancer, NSCLC
Cobimetinib
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Gemcitabine | Phase 3 | Pancreatic Cancer | - | - |
daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer) | - | - |
RMC-6236 | Phase 3 | Colorectal Cancer | - | - |
RMC-4630 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
RMC-6291 | Phase 2 | Non-Small Cell Lung Cancer, NSCLC | - | - |
Cobimetinib | Phase 2 | Solid Tumor | - | - |
Colorectal Cancer
1 drug in this indication
Non-Small Cell Lung Cancer, NSCLC
1 drug in this indication
Solid Tumor
1 drug in this indication
Pancreatic Cancer
1 drug in this indication
NSCLC (Non-small Cell Lung Cancer)
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)